Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 01, 2015 1:15 PM ET


Company Overview of ORCA Therapeutics B.V.

Company Overview

ORCA Therapeutics B.V., a biopharmaceutical company, designs and develops therapeutics for the treatment of cancer using Oncolytic Replication Competent Agents (ORCA). The ORCA agents/oncolytic viruses are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells, while healthy cells are left unharmed. The Oncolytic viruses serve as delivery agents to express anti-cancer products at high levels in cancer cells and as anti-cancer vaccines that present cancer antigens to the immune system. ORCA Therapeutics B.V. offers ORCA-010, a therapeutic for the treatment of patients with colorectal cancer metastasized in the liver. The company’s oncolytic virotherapy...

De Boelelaan 1118

Amsterdam,  1081 HZ


Founded in 2005


31 02 0444 1826

Key Executives for ORCA Therapeutics B.V.

Chief Executive Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

ORCA Therapeutics B.V. Key Developments

ORCA Therapeutics B.V. Presents at 2013 BIO Convention in China, Nov-11-2013

ORCA Therapeutics B.V. Presents at 2013 BIO Convention in China, Nov-11-2013 . Venue: China National Convention Center, No.7 Tianchen East Road, Chaoyang District, Beijing 100105, China.

ORCA Therapeutics BV Appoints Ronald Rodriguez to the Scientific Advisory Board

ORCA Therapeutics BV, announced that it has expanded its Scientific Advisory Board (SAB) with the appointment of Dr. Ronald Rodriguez. Dr. Rodriguez is currently Professor and Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio. He is an outstanding clinician and investigator focusing on prostate, bladder, and kidney cancer. Prof Ron Rodriguez will join existing members of ORCA’s SAB: Prof. Frank McCormick, Director of the Helen Diller Family Comprehensive Cancer Center & Cancer Research Institute of the University of California; Prof. Winald Gerritsen, medical oncologist at the Radboud University Nijmegen Medical Centre; and Dr. Ramon Alemany, laboratory director in the Catalan Institute of Oncology.

Similar Private Companies By Industry

Company Name Region
IQ Therapeutics BV Europe
Gelatine Smits Beheers BV Europe
Zoetis B.V. Europe
Crystallics B.V. Europe
Intervet International B.V. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORCA Therapeutics B.V., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at